At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Refresh Tears 0.5% Lubricant Eye Drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
In Brief
A Phase 4 clinical trial evaluating Refresh Tears 0.5% Lubricant Eye Drops and Bepreve 1.5% Ophthalmic Solution for Allergic Conjunctivitis. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
CollaboratorsBausch & Lomb Incorporated
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedMay 2011
Primary CompletionAug 2012
Study CompletionSep 2012
TodayJul 2026
First PostedMay 3, 2011
Enrollment StartMay 1, 2011
Primary CompletionAug 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.2 years ago
Interventions
Refresh Tears 0.5% Lubricant Eye Dropsdrug
Bepreve 1.5% Ophthalmic Solutiondrug